Is Microbot Medical Inc. (MBOT) a Buy, Sell, or Hold?
NASDAQ : MBOT
Microbot Medical Inc.
$1.77 USD
$0.05 (2.91%)
- Volume
- 372.04K
- Average Volume
- 1.18M
- Market Capitalization
- $80.66M
- P/E Ratio
- -6.40
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $4.67
- Year Low
- $1.60
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $22.59
Company Overview
NASDAQ
Harel Gadot
Medical - Instruments & Supplies
Healthcare
MBOT
43
US
USD
Liquidity Metrics
0.01
22.59
21.93
1.08
0.00
Sales & Valuation
-$
768.19
1.60
-5.24
-0.23
Profitability
-$0.29
-$13.14M
-13535.24%
-13535.24%
-21.84%
-18.21%
P/E Metrics
-6.40
-0.15
-0.15
Analyst Price Target & Rating
$4.00
$4.00
$4.00
2/5
3 Analysts
-55.75%
Financial Health Scores
10.60
3/9
$73.14M
$78.07M
$3.96M
-$14.21M
Key Metrics (TTM)
$75.62M
720.21
-5.34
22.59
-21.84%
-21.39%
-12.30%
-19.62%
4085 days
Company Executives
| Name | Title |
|---|---|
| Juan Diaz-Cartelle | Chief Medical Officer |
| Simon Sharon | Chief Technology Officer & GM of Microbot Israel |
| Harel Gadot | Co-Founder, President, Chief Executive Officer & Chairman |
| Christina Bailey | Vice President of Sales |
| Naama Moav | Vice President of Human Resources |
| Rachel Vaknin | Chief Financial Officer |
| Michael Lytle | Head of Sales Operations & Analytics |
| Allison Rosefort | Vice President of Marketing |
Poll Results
No votes yet today — be the first to share your view!
About Microbot Medical Inc. (NASDAQ:MBOT) Stock
Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompass ... ing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.
New Strong Buy Stocks for July 23rd
2026-07-23 08:01:08
PLGO, BLPD, INN, RFIL and MBOT have been added to the Zacks Rank #1 (Strong Buy) List on July 23, 2026.
2026-07-21 08:30:00
HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year's Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, in Fort Lauderdale, FL.
2026-07-07 08:30:00
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026 HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026.
2026-06-30 08:30:00
HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
2026-06-25 08:30:00
HINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has won the Innovative Start-Up Award from Surgical Robotics Technology (SRT), which recognizes companies with outstanding technological and commercial progress through highly innovative, groundbreaking technologies with the potential for broad healthcare impact.1 SRT, a leading platform for surgical robotics news, together with QNX, recognizes outstanding organizations, individuals, and technologies across the surgical robotics sector.
2026-06-23 08:30:00
Leading academic center with multi-hospital and multi-state health system deepens Company's footprint in the Northeast U.S. The Company now has multiple accounts and hospitals that have adopted the LIBERTY System across seven states in the U.S. HINGHAM, Mass., June 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that a globally recognized academic center headquartered in Pennsylvania is the first in the state to adopt the LIBERTY System, allowing the Company to further expand its presence in the Northeast U.S., joining other health systems in New York City and Boston that have also adopted the LIBERTY System.
2026-06-16 08:30:00
HINGHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into an agreement with Lovell® Government Services to serve federal healthcare systems, such as those administered by the Veterans Health Administration (VHA), a division of the U.S. Department of Veteran Affairs, the Military Health System (MHS), which is run by the U.S. Department of Defense, and the U.S. Indian Health Service (IHS).
2026-06-09 08:30:00
HINGHAM, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that one of the largest healthcare systems in Michigan is the first health network in Michigan and across the greater Midwest U.S. to adopt the LIBERTY System.
Frequently Asked Questions
-
What is the current Microbot Medical Inc. (MBOT) stock price?
-
Microbot Medical Inc.(NASDAQ:MBOT) stock price is $1.77 in the last trading session. During the trading session, MBOT stock reached the peak price of $4.67 while $1.6 was the lowest point it dropped to. The percentage change in MBOT stock occurred in the recent session was 2.91% while the dollar amount for the price change in MBOT stock was $0.05.
-
MBOT's industry and sector of operation?
-
The NASDAQ listed MBOT is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of MBOT?
-
Juan Diaz-Cartelle | Chief Medical Officer
Simon Sharon | Chief Technology Officer & GM of Microbot Israel
Harel Gadot | Co-Founder, President, Chief Executive Officer & Chairman
Christina Bailey | Vice President of Sales
Naama Moav | Vice President of Human Resources -
How many employees does MBOT have?
-
Number of MBOT employees currently stands at 43. MBOT operates from 175 Derby Street, Hingham, MA 02043, US.
-
Link for MBOT official website?
-
Official Website of MBOT is: https://www.microbotmedical.com
-
How do I contact MBOT?
-
MBOT could be contacted at phone #781 875 3605 and can also be accessed through its website. MBOT operates from 175 Derby Street, Hingham, MA 02043, US.
-
How many shares of MBOT are traded daily?
-
The average number of MBOT shares traded daily for last 3 months was 1.18M.
-
What is the market cap of MBOT currently?
-
The market value of MBOT currently stands at $80.66M with its latest stock price at $1.77